International experience of using olaparib for metastatic castration-resistant prostate cancer: literature review

Cover Page

Cite item

Full Text

Abstract

The following review presents a problem of metastatic castration-resistant prostate cancer and its association with germline or somatic mutations in homologous recombination repair (HRR). In 2020, olaparib was approved in the Russian Federation as a monotherapy for metastatic castration-resistant prostate cancer with germline or somatic mutations of genes involved in DNA repair by homologous recombination, after progression on therapy with new hormonal drugs. We describe a review of the main olaparib clinical trials assessing its efficacy, safety and tolerance in metastatic castration-resistant prostate cancer patients.

About the authors

V. B. Matveev

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Author for correspondence.
Email: vsevolodmatveev@mail.ru
ORCID iD: 0000-0001-7748-9527

24 Kashirskoe Shosse, Moscow 115478

Russian Federation

O. A. Khalmurzaev

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

ORCID iD: 0000-0001-7500-1815

24 Kashirskoe Shosse, Moscow 115478

Russian Federation

O. I. Evsyukova

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

ORCID iD: 0000-0002-3016-6357

24 Kashirskoe Shosse, Moscow 115478

Russian Federation

References

  1. Prostate cancer. Clinical guideline. Russian Society of Urologists, Russian Association of Oncologists, Russian Association of Oncological Urology, Russian Society of Clinical Oncology. Available at: http://www.oncology.ru/association/clinical-guidelines/2018/rak_predstatelnoy_zhelezy_pr2018.pdf. (In Russ.).
  2. State of oncological care in Russia in 2019. Eds.: A.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2020. 239 p. (In Russ.).
  3. Mateo J., Carreira S., Seed G. et al. Genomic profiling of primary prostate tumors from patients who develop metastatic castration-resistant prostate cancer (mCRPC). American Society of Clinical Oncology, 2018. doi: 10.1200/JCO.2018.36.15_suppl.5013.
  4. Mateo J., Boysen G., Barbieri C.E. et al. DNA repair in prostate cancer: biology and clinical implications. Eur Urol 2017;71(3):417-25. doi: 10.1016/j.eururo.2016.08.037.
  5. Nicolosi P., Ledet E., Yang S. et al. Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines. JAMA Oncol 2019;5(4):523-8. doi: 10.1001/jamaoncol.2018.6760.
  6. Castro E., Romero-Laorden N., Del Pozo A. et al. PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2019;37(6):490-503. doi: 10.1200/JCO.18.00358.
  7. Castro E., Goh C., Olmos D. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol 2013;31(14):1748-57. doi: 10.1200/JCO.2012.43.1882.
  8. Castro E., Goh C., Leongamornlert D. et al. Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer. Eur Urol 2015;68(2):186-93. doi: 10.1016/j.eururo.2014.10.022.
  9. Pavlov A.Yu., Gafanov R.A., Kravcov I.B., Fastovec S.V. PARP inhibitors are a new area in the treatment of breast cancer. Russkiy meditsinskiy zhurnal = Russian Medical Journal 2017;25(16):1172-4. (In Russ.).
  10. Morales J.C., Li L., Fattah F.J. et al. Review of poly(ADP-ribose)polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases. Crit Rev Eukaryot Gene Expr 2014;24(1):15-28. doi: 10.1615/critreveukaryotgeneexpr.2013006875.
  11. Dziadkowiec K.N., G^siorowska E., Nowak-Markwitz E., Jankowska A. PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting. Prz Menopauzalny 2016;15(4):215-9. doi: 10.5114/pm.2016.65667.
  12. Registration certificate LP-003716 dated 11.07.2016 for Lynparza® (olaparib), 50-mg capsules, manufactured by AstraZeneca UK (UK) [Internet]. State Register of Medicines. Available at: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=b450c3e5-ff97-4d8d-b490-f12cc9c240a5&t=. (In Russ.).
  13. AstraZeneca Canada Inc. Product monograph. Lynparza®. Olaparib Tablets, 100 mg and 150 mg, oral [Internet]. 2020. Available at: https://www.astrazeneca.ca/content/dam/az-ca/downloads/productinformation/lynparza-tablets-product-monograph-en.pdf.
  14. Olaparib (Professional Patient Advice) [Internet]. Drugs.com. Available at: https://www.drugs.com/ppa/olaparib.html.
  15. EMA. List of Union reference dates and frequency of submission of periodic safety update reports (PSURs). 2018.
  16. Kaufman B., Shapira-Frommer R., Schmutzler R.K. et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 2015;33(3):244-50. doi: 10.1200/JCO.2014.56.2728.
  17. Mateo J., Porta N., Bianchini D., McGovern U. et al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 2020;21(1):162-74. doi: 10.1016/S1470-2045(19)30684-9.
  18. Ma Y., He L., Huang Q. et al. Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report. BMC Med Gen 2018;19(1):185. doi: 10.1186/s12881-018-0703-9.
  19. Clarke N., Wiechno P., Alekseev B. et al. Olaparib combined with abiraterone in patients with metastatic castrationresistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 2018;19(7):975-86. doi: 10.1016/S1470-2045(18)30365-6.
  20. Clarke N.W., Armstrong A.J., Thiery-Vuillemin A. et al. PROpel: a randomized, phase III trial evaluating the efficacy and safety of olaparib combined with abiraterone as first-line therapy in patients with metastatic castrationresistant prostate cancer (mCRPC). J Clin Oncol 2019;37(7):suppl.
  21. Study on olaparib plus abiraterone as first-line therapy in men with metastatic castration-resistant prostate cancer [Internet]. ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT03732820.
  22. De Bono J., Mateo J., Fizazi K. et al. Olaparib for metastatic castrationresistant prostate cancer. N Eng J Med 2020;382(22):2091-102. doi: 10.1056/NEJMoa1911440.
  23. Instructions for medical use of the drug Linparza, film-coated tablets, 100 and 150 mg (ЛП-005941 dated 11.26.2019), taking into account change 2 dated 11.03.2020. (In Russ.).

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-36986 от  21.07.2009.